Exelixis

Exelixis ROIC

The Return on Invested Capital (ROIC) of Exelixis (EXEL) as of Nov 11, 2026 is 36.21 %. In the previous year, Return on Invested Capital (ROIC) was 22.97 % — a change of 57.62% (higher).

ROIC

36.21 %

YoY

57.62%

Last updated:

Return on Invested Capital (ROIC) of Exelixis is 2025 36.21 % . Return on Invested Capital (ROIC) of Exelixis was 2024 22.97 % . It decreases by 57.62% higher compared to the previous year.

The Exelixis ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
51.33 USD
Jan 1, 2019
19.04 USD
Jan 1, 2020
5.95 USD
Jan 1, 2021
10.45 USD
Jan 1, 2022
7.33 USD
Jan 1, 2023
9.07 USD
Jan 1, 2024
22.97 USD
Jan 1, 2025
36.21 USD
The Exelixis ROIC history
YEARROICYoY
36.21 %+57.62%
22.97 %+153.15%
9.07 %+23.88%
7.33 %-29.92%
10.45 %+75.71%
5.95 %-68.76%
19.04 %-62.91%
51.33 %+18.80%
43.21 %-271.31%
-25.22 %-58.83%
-61.26 %-44.76%
-110.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

Return on Invested Capital (ROIC) of Exelixis is 36.21 % in 2025.

Return on Invested Capital (ROIC) of Exelixis changed from 22.97 % to 36.21 %, representing a 57.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Exelixis since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Exelixis with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Exelixis

All Key Metrics — Exelixis